Healthcare - Drug Manufacturers - Specialty & Generic - NYSE - GB
$ 9.39
0.859 %
$ 42.5 B
Market Cap
27.62
P/E
CASH FLOW STATEMENT
1.72 B
OPERATING CASH FLOW
-134 M
INVESTING CASH FLOW
-1.57 B
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Haleon plc
| Net Income | 1.05 B |
| Depreciation & Amortization | 309 M |
| Capital Expenditures | -336 M |
| Stock-Based Compensation | 76 M |
| Change in Working Capital | -107 M |
| Others | 1.32 B |
| Free Cash Flow | 1.39 B |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | 1 049.0 | 1 119.0 | 1 439.0 | 1 181.0 | 687.0 |
| Depreciation & Amortization | 309.0 | 287.0 | 268.0 | 305.0 | 260.0 |
| Deferred Income Tax | (675.0) | 62.0 | 197.0 | 410.0 | 199.0 |
| Stock Based Compensation | 76.0 | 15.0 | 59.0 | 63.0 | 58.0 |
| Other Operating Activities | 1 448.0 | 353.0 | (20.0) | 198.0 | 362.0 |
| Change in Working Capital | (107.0) | 181.0 | (152.0) | 15.0 | (461.0) |
| Cash From Operations | 2 100.0 | 2 063.0 | 1 356.0 | 1 407.0 | 786.0 |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | (336.0) | (328.0) | (298.0) | (318.0) | (243.0) |
| Other Items | 202.0 | (8 456.0) | 265.0 | 1 348.0 | 534.0 |
| Cash From Investing Activities | (134.0) | (8 784.0) | (33.0) | 1 030.0 | 291.0 |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | (38.0) | 0 | 0 | 0 | 0 |
| Total Debt Repaid | (553.0) | 9 486.0 | 8.0 | 28.0 | 1.0 |
| Dividends Paid | (388.0) | (2 682.0) | (1 148.0) | (2 371.0) | (1 152.0) |
| Other Financing Activities | (627.0) | 107.0 | (96.0) | (94.0) | 226.0 |
| Cash From Financing Activities | (1 568.0) | 6 911.0 | (1 236.0) | (2 437.0) | (925.0) |
| CHANGE IN CASH | |||||
| Net Change In Cash | 360.0 | 205.0 | 82.0 | (6.0) | 138.0 |
| FREE CASH FLOW | |||||
| Free Cash Flow | 1 387.0 | 1 735.0 | 1 058.0 | 1 089.0 | 543.0 |